Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
View/Open
Author
Ávila-Nieto, Carlos
Amengual-Rigo, Pep
Ainsua-Enrich, Erola
Rodríguez de la Concepción, María Luisa
Pedreño-Lopez, Núria
Urrea, Victor
Pradenas, Edwards
Marfil, Silvia
Ballana, Ester
Riveira-Muñoz, Eva
Roca, Núria
Pons-Grífols, Anna
Rovirosa, Carla
Aguilar-Gurrieri, Carmen
Ortiz, Raquel
Barajas, Ana
Trinité, Benjamin
Lepore, Rosalba
Muñoz-Basagoiti, Jordana
Perez-Zsolt, Daniel
Izquierdo-Useros, Nuria
Valencia, Alfonso
Blanco, Julià
Guallar, Victor
Clotet, Bonaventura
Carrillo, Jorge
Publication date
2024-03-21ISSN
2041-1723
Abstract
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccines are crucial to fight against the coronavirus disease 2019
pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the
V987H mutation that increases by two-fold the production of the recombinant
Spike and the exposure of the receptor binding domain (RBD). S-V987H
immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH),
and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2
challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-
hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated
animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus,
S-V987H protein might be considered for future SARS-CoV-2 vaccines
development.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
619 - Veterinary science
Pages
18
Publisher
Nature Research
Is part of
Nature Communications
Citation
Ávila‐Nieto, Carlos, Júlia Vergara‐Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, Maria Luisa Rodrı́Guez De La Concepción, Núria Pedreño-López, et al. 2024. “Immunization With V987H-stabilized Spike Glycoprotein Protects K18-hACE2 Mice and Golden Syrian Hamsters Upon SARS-CoV-2 Infection.” Nature Communications 15 (1): 2349. doi:10.1038/s41467-024-46714-w.
Grant agreement number
ISCII/Programa Estatal de fomento de la investigación científica y técnica de excelencia/PI17-01518/ES/Desarrollo de una plataforma de vacunas contra el VIH basada en partículas similares a virus (VLP) envueltas y de alta densidad antigénica/
ISCII/Programa Estatal de fomento de la investigación científica y técnica de excelencia/PI18-01332/ES/Identificación, aislamiento y caracterización de anticuerpos que interfieren con la acción de los anticuerpos neutralizantes en personas infectadas por el virus de la inmunodeficiencia humana/
MICINN/Programa Estatal de I+D+I orientada a los retos de la sociedad/PID2020-117145RB-I00/ES/Nuevas terapias antivirales e inmunomoduladoras frente al SARS-CoV-2/
EU/H2020/101046118/EC/RBD Dimer recombinant protein vaccine against SARSCoV2/RBDCOV
Program
Sanitat Animal
This item appears in the following Collection(s)
- ARTICLES CIENTÍFICS [2555]
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/